Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial

被引:4
|
作者
Quintana-Hernandez, Domingo J. [1 ]
Rojas-Hernandez, Jaime [2 ]
Santana-Del Pino, Angelo [3 ]
Cespedes Suarez, Carmen [1 ]
Pellejero Silva, Monica [4 ]
Teresa Miro-Barrachina, Maria [5 ]
Ibanez Fernandez, Ignacio [5 ]
Estupinan Lopez, Jose Antonio [2 ]
Borkel, Lucas F. [6 ]
机构
[1] Atlantico Medio Univ, Dept Psychol, Tafira Baja, Spain
[2] Assoc Canaria Desarrollo Salud Traves Atenc, Las Palmas Gran Canaria, Spain
[3] Las Palmas de Gran Canaria Univ, Dept Math, Las Palmas Gran Canaria, Spain
[4] Atlantico Medio Univ, Dept Commun, Tafira Baja, Spain
[5] La Laguna Univ, Dept Clin Psychol Psychobiol & Methodol, San Cristobal la Laguna, Spain
[6] Assoc Cient Psicodel, Las Palmas Gran Canaria, Spain
关键词
Alzheimer's disease; cognitive stimulation; mindfulness; randomized clinical trial; relaxation; EPIDEMIOLOGY; DEMENTIA;
D O I
10.3233/JAD-220889
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: This longitudinal study addressed whether mindfulness practice prevents psychological and behavioral symptoms, especially mood disorders, in Alzheimer's disease (AD). Objective: To assess the incidence of depression in the course of AD and to determine which non-pharmacological treatment (NPT) is most effective in preventing psychopathological symptoms. Methods: We conducted a longitudinal, non-inferiority and equivalence randomized clinical trial, repeated-measures design, with a control group and three experimental treatments: mindfulness, cognitive stimulation, and relaxation. Each experimental group performed three weekly sessions for two years. The pharmacological treatment of all participants was donepezil (10 mg). Participants were patients with probable AD without diagnosed depression from the public neurology services of the Canary Health Service, Spain. Psychological evaluation was performed using the Geriatric Depression Scale (GDS), Hamilton Depression Rating Scale (HDRS), and Neuropsychiatric Inventory (NPI-Q). The statistical analysis included only patients who attended at least 75% of the sessions. A nonparametric, repeated-measures analysis was performed with Kruskal-Wallis H test and between-group differences with Mann-Whitney U test with Bonferroni correction (p < 0.008). Effect size was calculated with partial eta-squared. Results: The results showed significant differences with large effect sizes (eta(2)(p)>0.14) between mindfulness and the rest of the experimental groups as well as the control in the GDS, HDRS, and NPI-Q scales. Conclusion: Compared to the other experimental groups, only mindfulness prevented the onset of depression and other psychopathologies in early-stage AD. Based on its effectiveness in maintaining cognitive functions and preventing psychopathology, we recommend mindfulness as the first-choice NPT for mild to moderate AD.
引用
收藏
页码:471 / 481
页数:11
相关论文
共 50 条
  • [41] Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials
    Gauthier, Serge
    Proano, Jefferson Voltaire
    Jia, Jianping
    Froelich, Lutz
    Vester, Johannes Christophe
    Doppler, Edith
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 39 (5-6) : 332 - 347
  • [42] The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease
    Raj C Shah
    Patrick J Kamphuis
    Sue Leurgans
    Sophie H Swinkels
    Carl H Sadowsky
    Anke Bongers
    Stephen A Rappaport
    Joseph F Quinn
    Rico L Wieggers
    Philip Scheltens
    David A Bennett
    Alzheimer's Research & Therapy, 5
  • [43] The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease
    Shah, Raj C.
    Kamphuis, Patrick J.
    Leurgans, Sue
    Swinkels, Sophie H.
    Sadowsky, Carl H.
    Bongers, Anke
    Rappaport, Stephen A.
    Quinn, Joseph F.
    Wieggers, Rico L.
    Scheltens, Philip
    Bennett, David A.
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (06):
  • [44] A 12-week clinical trial of talsaclidine, a muscarinic agonist, in the treatment of mild to moderate Alzheimer's disease
    Jones, R
    Raschig, A
    Müller, A
    Müller, S
    Ingelheim, B
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S122 - S122
  • [45] Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
    Yuqi Qiu
    Diane M. Jacobs
    Karen Messer
    David P. Salmon
    Cheryl L. Wellington
    Sophie Stukas
    Carolyn Revta
    James B. Brewer
    Gabriel C. Léger
    Brianna Askew
    Lia Donahue
    Stephen Kaplita
    Vladimir Coric
    Irfan A. Qureshi
    Howard H. Feldman
    Alzheimer's Research & Therapy, 17 (1)
  • [46] Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
    Peskind, Elaine R.
    Potkin, Steven G.
    Pomara, Nunzio
    Ott, Brian R.
    Graham, Stephen M.
    Olin, Jason T.
    McDonald, Scott
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (08): : 704 - 715
  • [47] Retest reliability of balance and mobility measurements in people with mild to moderate Alzheimer's disease
    Suttanon, Plaiwan
    Hill, Keith D.
    Dodd, Karen J.
    Said, Catherine M.
    INTERNATIONAL PSYCHOGERIATRICS, 2011, 23 (07) : 1152 - 1159
  • [48] Dimebon improves cognitive function in people with mild to moderate Alzheimer's disease COMMENT
    Gauthier, Serge
    EVIDENCE-BASED MENTAL HEALTH, 2009, 12 (01) : 21 - 21
  • [49] Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
    Pakdaman, Hossein
    Harandi, Ali Amini
    Hatamian, Hamidreza
    Tabatabae, Mojgan
    Kasmaei, Hosein Delavar
    Ghassemi, Amirhossein
    Gharagozli, Koroush
    Ashrafi, Farzad
    Naeini, Pardis Emami
    Tavakolian, Mehrnaz
    Shahin, Darush
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2015, 5 (01): : 96 - 106
  • [50] Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease
    Dartigues, JF
    Goulley, F
    Bourdeix, I
    Péré, JJ
    Barberger-Gateau, P
    REVUE NEUROLOGIQUE, 2002, 158 (8-9) : 807 - 812